Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Stephen P. CareySVP & CFO | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 09/29 | 09/30 | 2,850 sh | $73.00 | $208,050 | −1.7% |
Stephen P. CareySVP & CFO | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 06/29 | 06/30 | 2,850 sh | $84.12 | $239,742 | −1.6% |
Meredith CookSr. Vp, General Counsel & Sec | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 06/12 | 06/15 | 500 sh | $82.03 | $41,015 | −0.6% |
Thomas HaugheyDirector | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 06/08 | 06/10 | 2,000 sh | $80.88 | $161,760 | −4.9% |
Stephen P. CareySVP & CFO | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 06/05 | 06/09 | 3,312 sh | $80.00 | $264,960 | −1.8% |
Ani PharmaceuticalsANIP | Open-market sale | 05/11–05/13 | 05/13 | 13,973 sh2 trades | $80.66avg. | $1,127,119.75 | −26.7% | |
Meredith CookSr. Vp, General Counsel & Sec | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 05/13 | 05/13 | 500 sh | $78.16 | $39,080 | −0.6% |
Thomas Andrew RowlandSVP, Head - Established Brands | Ani PharmaceuticalsANIP | Open-market sale | 05/12 | 05/13 | 459 sh | $79.21 | $36,357.39 | −1.2% |
Ori GutwergSVP, Generics | Ani PharmaceuticalsANIP | Open-market sale | 05/12 | 05/13 | 2,772 sh | $79.50 | $220,374 | −3.4% |
Nikhil LalwaniPresident & CEO | Ani PharmaceuticalsANIP | Open-market sale | 05/11 | 05/13 | 55,000 sh | $77.57 | $4,266,350 | −13.6% |
Meredith CookSr. Vp, General Counsel & Sec | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 04/13 | 04/13 | 500 sh | $77.95 | $38,975 | −0.6% |
Christopher MutzHead of Rare Disease | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 03/13 | 03/13 | 3,162 sh | $71.64 | $226,525.68 | −3.3% |
Meredith CookSr. Vp, General Counsel & Sec | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 03/13 | 03/13 | 500 sh | $72.62 | $36,310 | −0.6% |
Thomas Andrew RowlandSVP, Head - Established Brands | Ani PharmaceuticalsANIP | Open-market sale | 03/11 | 03/13 | 4,772 sh | $74.91 | $357,470.52 | −11.0% |
Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 03/06–03/09 | 03/10 | 5,723 sh2 trades | $74.19avg. | $424,616.98 | −5.7% | |
Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 03/06–03/09 | 03/10 | 6,572 sh2 trades | $74.33avg. | $488,474.31 | −11.2% | |
Ani PharmaceuticalsANIP | Open-market sale | 03/05 | 03/05 | 7,312 sh2 trades | $75.50avg. | $552,031.04 | −3.8% | |
Ori GutwergSVP, Generics | Ani PharmaceuticalsANIP | Open-market sale | 03/03 | 03/04 | 2,060 sh | $76.50 | $157,590 | −2.4% |
Christopher MutzHead of Rare Disease | Ani PharmaceuticalsANIP | Open-market sale10b5-1 plan | 03/02 | 03/04 | 417 sh | $74.00 | $30,858 | −0.4% |
Patrick D. WalshDirector | Ani PharmaceuticalsANIP | Open-market sale | 03/03 | 03/03 | 6,000 sh | $74.23 | $445,380 | −10.3% |